Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) is 59.48% higher on its value in year-to-date trading and has touched a low of $0.92 and a high of $3.79 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LXRX stock was last observed hovering at around $2.52 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $2.44, the stock is -0.49% and 12.92% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.89 million and changing -3.17% at the moment leaves the stock 39.11% off its SMA200. LXRX registered 8.44% gain for a year compared to 6-month gain of 99.18%. The firm has a 50-day simple moving average (SMA 50) of $958.66 and a 200-day simple moving average (SMA200) of -$3.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -23.27% loss in the last 1 month and extending the period to 3 months gives it a 92.13%, and is -3.17% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.71% over the week and 11.45% over the month.
Lexicon Pharmaceuticals Inc (LXRX) has around 135 employees, a market worth around $597.63M and $1.21M in sales. Profit margin for the company is -14573.20%. Distance from 52-week low is 165.22% and -35.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-90.46%).
Lexicon Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.2 with sales reaching $1.37M over the same period.The EPS is expected to grow by 10.07% this year, but quarterly earnings will post 2,043.70% year-over-year. Quarterly sales are estimated to grow 5,608.30% in year-over-year returns.
Lexicon Pharmaceuticals Inc (LXRX) Top Institutional Holders
146 institutions hold shares in Lexicon Pharmaceuticals Inc (LXRX), with institutional investors hold 78.88% of the company’s shares. The shares outstanding are 244.93M, and float is at 238.24M with Short Float at 8.84%. Institutions hold 77.58% of the Float.
The top institutional shareholder in the company is Artal Group S.A. with over 117.55 million shares valued at $269.2 million. The investor’s holdings represent 48.00% of the LXRX Shares outstanding. As of Jun 29, 2023, the second largest holder is BVF Inc. with 20.0 million shares valued at $45.79 million to account for 8.16% of the shares outstanding. The other top investors are FMR, LLC which holds 8.51 million shares representing 3.47% and valued at over $19.49 million, while Vanguard Group Inc holds 2.64% of the shares totaling 6.46 million with a market value of $14.79 million.
Lexicon Pharmaceuticals Inc (LXRX) Insider Activity
The most recent transaction is an insider purchase by COATS LONNEL,the company’sChief Executive Officer. SEC filings show that COATS LONNEL bought 90,000 shares of the company’s common stock on Nov 16 ’23 at a price of $1.05 per share for a total of $94797.0. Following the purchase, the insider now owns 0.91 million shares.
Lexicon Pharmaceuticals Inc disclosed in a document filed with the SEC on Nov 10 ’23 that COATS LONNEL (Chief Executive Officer) bought a total of 10,000 shares of the company’s common stock. The trade occurred on Nov 10 ’23 and was made at $1.01 per share for $10100.0. Following the transaction, the insider now directly holds 0.82 million shares of the LXRX stock.
Still, SEC filings show that on Oct 12 ’23, DEBBANE RAYMOND (Director) acquired 148,820 shares at an average price of $1.03 for $0.15 million. The insider now directly holds 1,340,847 shares of Lexicon Pharmaceuticals Inc (LXRX).
